CNMD guides 6%-8% H2 2024 revenue growth on margin expansion
Management cites strong Q2 performance and confidence in 6%-8% revenue growth for H2 2024, citing AirSeal, BioBrace and international expansion. Margin expansion and robust free cash flow supported by sales and R&D investments.
Story updates
06:20:53 PM UTC
SquawkNews
Management highlighted accelerated growth driven by strong performance in minimally invasive surgery and sports medicine, with AirSeal, BioBrace, and Buffalo Filter as key growth drivers. International expansion, margin improvement, and ongoing investment in sales and R&D support the outlook, while…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.